TY - JOUR
T1 - Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma
AU - Wharton, J. Taylor
AU - Herson, Jay
AU - Edwards, Creighton L.
AU - Griffith, Augusta B.
N1 - Funding Information:
’ Supported in part by Research Grants CA-6294 and CA-11430 and Contract NOl-33710 National Cancer Institute, U.S. Department of Health, Education, and Welfare. ’ To whom reprint requests should be addressed.
PY - 1982/10
Y1 - 1982/10
N2 - Singleagent Adriamycin (ADM) induced a 21.8% response rate, surgically documented, in 32 previously untreated patients with advanced ovarian cancer. Patients with grade 3 carcinomas had a longer survival time than patients with grade 2 carcinomas (P = 0.07). A statistically significant interaction of grade and age was found (P = 0.01). Patients younger than 45 years had almost precisely the same risk of death per unit time, regardless of grade. Patients over age 45, with grade 3 tumors, had 3.6 times the risk of death per unit time, and those with grade 2 tumors had 45.5 times the risk as the patient under 45 years of age. Hexamethylmelamine-cyclophosphamide was active in four patients (17%) who failed to respond to ADM. ADM may exert significant but selective anti-tumor activity and deserves additional testing in drug combinations used in the treatment of ovarian cancer.
AB - Singleagent Adriamycin (ADM) induced a 21.8% response rate, surgically documented, in 32 previously untreated patients with advanced ovarian cancer. Patients with grade 3 carcinomas had a longer survival time than patients with grade 2 carcinomas (P = 0.07). A statistically significant interaction of grade and age was found (P = 0.01). Patients younger than 45 years had almost precisely the same risk of death per unit time, regardless of grade. Patients over age 45, with grade 3 tumors, had 3.6 times the risk of death per unit time, and those with grade 2 tumors had 45.5 times the risk as the patient under 45 years of age. Hexamethylmelamine-cyclophosphamide was active in four patients (17%) who failed to respond to ADM. ADM may exert significant but selective anti-tumor activity and deserves additional testing in drug combinations used in the treatment of ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=0019920185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019920185&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(82)90098-1
DO - 10.1016/0090-8258(82)90098-1
M3 - Article
C2 - 6813202
AN - SCOPUS:0019920185
SN - 0090-8258
VL - 14
SP - 262
EP - 270
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -